why does nobody talk about amylin
The title is the whole question — why does nobody talk about amylin — but here is why I am asking.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
phase 3 data will change most of what gets said here
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Retitled to distinguish the combination arm from the monotherapy arm, which the original ran together.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
nothing here is approved as a standalone product and research material is not for human use
amylin and GLP-1 are not redundant pathways
- 1Combination and monotherapy arms must be read separately. Efficacy and…8 comments in this branch · started by u/hugo_pires